Lyell Immunopharma (NASDAQ:LYEL) Given “Buy” Rating at HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $45.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 202.22% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Citizens Jmp assumed coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective on the stock. Robert W. Baird set a $49.00 price objective on Lyell Immunopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Price Performance

LYEL stock opened at $14.89 on Wednesday. The firm has a 50 day simple moving average of $20.39 and a two-hundred day simple moving average of $23.58. The stock has a market cap of $347.44 million, a PE ratio of -1.08 and a beta of -0.09. Lyell Immunopharma has a one year low of $7.78 and a one year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting the consensus estimate of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, research analysts expect that Lyell Immunopharma will post -8.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BBR Partners LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $210,000. ExodusPoint Capital Management LP bought a new position in Lyell Immunopharma during the 4th quarter worth approximately $262,000. Marshall Wace LLP bought a new position in Lyell Immunopharma during the 2nd quarter worth approximately $94,000. Jane Street Group LLC purchased a new position in Lyell Immunopharma in the 4th quarter worth approximately $382,000. Finally, Barclays PLC lifted its position in Lyell Immunopharma by 1,239.5% in the fourth quarter. Barclays PLC now owns 15,967 shares of the company’s stock valued at $491,000 after purchasing an additional 14,775 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.